Qiagen (NYSE:QGEN) had its price objective increased by investment analysts at Morgan Stanley from $38.00 to $39.00 in a research note issued on Wednesday, Stock Target Advisor reports. The firm currently has an “overweight” rating on the stock. Morgan Stanley’s price target would suggest a potential upside of 12.91% from the stock’s previous close.

Several other analysts also recently weighed in on QGEN. ValuEngine upgraded Qiagen from a “hold” rating to a “buy” rating in a research note on Monday, July 2nd. Deutsche Bank upped their price target on Qiagen from $43.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, October 5th. Citigroup upped their price target on Qiagen from $35.00 to $38.00 and gave the stock a “neutral” rating in a research note on Thursday, August 2nd. Commerzbank restated a “buy” rating on shares of Qiagen in a research note on Tuesday, August 7th. Finally, Bank of America upped their price target on Qiagen from $38.00 to $39.00 and gave the stock a “neutral” rating in a research note on Thursday, August 2nd. Five analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $40.60.

Qiagen stock opened at $34.54 on Wednesday. The company has a current ratio of 1.79, a quick ratio of 1.62 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $8.65 billion, a P/E ratio of 27.20, a P/E/G ratio of 2.34 and a beta of 1.10. Qiagen has a twelve month low of $30.20 and a twelve month high of $39.45.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Tuesday, July 31st. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.01. The company had revenue of $377.20 million for the quarter, compared to the consensus estimate of $376.89 million. Qiagen had a return on equity of 12.22% and a net margin of 5.26%. On average, analysts expect that Qiagen will post 1.33 EPS for the current fiscal year.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

See Also: Earnings Per Share

Stock Target Advisor

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.